Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. More Details
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Avid Bioservices's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CDMO's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CDMO exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: CDMO exceeded the US Market which returned 39.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Avid Bioservices's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StIf You Had Bought Avid Bioservices (NASDAQ:CDMO) Stock Five Years Ago, You Could Pocket A 633% Gain Today
2 months ago | Simply Wall StAvid Bioservices, Inc. (NASDAQ:CDMO) Could Be Less Than A Year Away From Profitability
3 months ago | Simply Wall StHow Much Of Avid Bioservices, Inc. (NASDAQ:CDMO) Do Institutions Own?
Is Avid Bioservices undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CDMO ($24.3) is trading above our estimate of fair value ($0.5)
Significantly Below Fair Value: CDMO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CDMO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CDMO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDMO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDMO is overvalued based on its PB Ratio (17.3x) compared to the US Biotechs industry average (3.4x).
How is Avid Bioservices forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDMO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CDMO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDMO's is expected to become profitable in the next 3 years.
Revenue vs Market: CDMO's revenue (25.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CDMO's revenue (25.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CDMO's Return on Equity is forecast to be high in 3 years time (35.2%)
How has Avid Bioservices performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDMO is currently unprofitable.
Growing Profit Margin: CDMO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDMO is unprofitable, but has reduced losses over the past 5 years at a rate of 30.8% per year.
Accelerating Growth: Unable to compare CDMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: CDMO has a negative Return on Equity (5.22%), as it is currently unprofitable.
How is Avid Bioservices's financial position?
Financial Position Analysis
Short Term Liabilities: CDMO's short term assets ($116.3M) exceed its short term liabilities ($62.6M).
Long Term Liabilities: CDMO's short term assets ($116.3M) exceed its long term liabilities ($20.2M).
Debt to Equity History and Analysis
Debt Level: CDMO is debt free.
Reducing Debt: CDMO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CDMO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CDMO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 37.4% per year.
What is Avid Bioservices's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDMO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nick Green (55 yo)
Mr. Nicholas Stewart Green, also known as Nick, B.Sc., MBA, has been the President, Chief Executive Officer and Director at Avid Bioservices, Inc. since July 30, 2020. He served as the Chief Executive Offi...
Experienced Management: CDMO's management team is considered experienced (2.3 years average tenure).
Experienced Board: CDMO's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.7%.
Avid Bioservices, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Avid Bioservices, Inc.
- Ticker: CDMO
- Exchange: NasdaqCM
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.442b
- Shares outstanding: 60.83m
- Website: https://www.avidbio.com
Number of Employees
- Avid Bioservices, Inc.
- 2642 Michelle Drive
- Suite 200
- United States
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services fo...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 03:12|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.